Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of andarine(s4) capsule in China. Welcome to wholesale bulk high quality andarine(s4) capsule for sale here from our factory. Good service and reasonable price are available.
Andarine (S4) is a selective androgen receptor modulator (SARM), originally developed by GTx Company, for the treatment of conditions such as muscle atrophy and osteoporosis. Its mechanism of action is to selectively activate androgen receptors in skeletal muscles and bone tissues, promoting muscle growth and bone density enhancement, while reducing stimulation of tissues such as the prostate and sebaceous glands, thereby reducing the side effects of traditional steroids.
Andarine(S4) capsules are its oral formulation. The common dosage is 25-50mg per day, taken in divided doses to maintain blood drug concentration. Users typically report significant effects in muscle growth, fat loss, and enhancing athletic performance, especially for fitness and competitive athletes. However, it may cause mild side effects such as visual persistence (temporary light sensitivity or reduced night vision) and hormonal fluctuations, which usually recover after discontinuation.
Since S4 has not yet been approved by the FDA, its long-term safety needs to be studied. Use should be cautious and under professional guidance. When purchasing, pay attention to product purity and avoid counterfeit and substandard products.
|
|
|
Andarine Powder COA
Core Function Positioning: Breakthrough in Selective Androgen Receptor Regulation
The core function of Andarine(S4) Capsule stems from its characteristic as a selective androgen receptor modulator (SARM). Unlike traditional anabolic steroids, S4 achieves tissue-specific anabolic effects by highly selectively binding to androgen receptors (AR) in skeletal muscle and bone tissues. Its key parameters include:
Affinity: The binding constant (Ki) with AR is 4 nM, comparable to that of testosterone, but it only activates the target tissue receptors.
Transcriptional activity: At a concentration of 10 nM, it can activate 93% of AR-mediated transcription and promote protein synthesis.
Metabolic stability: The oral bioavailability increases with the dose (38% at 0.1 mg/kg and 91% at 10 mg/kg), with a half-life of approximately 4 hours, supporting multiple dosing.
Mechanism of Function Realization: Triple Action Pathway
Muscle anabolic metabolism enhancement
S4 activates skeletal muscle AR, promoting satellite cell proliferation and muscle fiber hypertrophy. Animal experiments show that an 8-week intervention can increase rat grasping force by 22% and swimming endurance by 31%. The mechanisms include:
Increasing the rate of muscle protein synthesis while inhibiting protein breakdown mediated by the ubiquitin-proteasome system.
Increasing muscle mitochondrial density, enhancing fat oxidation energy supply capacity, and maintaining muscle mass even in the presence of insufficient calories.
Fat oxidation and body composition optimization
S4 is the compound with the highest androgen index and the lowest anabolic index among SARM products. Its fat breakdown effect is achieved through the following pathways:
Activating adipose tissue AR, inducing fat enzyme expression, promoting triglyceride hydrolysis into free fatty acids.
Increasing muscle vascular distribution, enhancing local blood flow, and accelerating fat acid transport to muscles for energy supply.
Clinical data show that the 75 mg/day dose group has a 3.2% decrease in body fat percentage and a 1.8 kg increase in lean body mass within 12 weeks.
Bone density improvement and osteoporosis prevention
S4 activates osteoblast AR, promoting the secretion of bone formation markers (such as alkaline phosphatase and osteocalcin), and simultaneously inhibiting osteoclast activity. In castrated rat models:
A 0.5 mg/day dose can increase femoral bone density by 12% and increase trabecular bone thickness by 21%.
Compared with bisphosphonate drugs, S4 does not cause severe side effects such as mandibular osteonecrosis.
Functional Application Scenarios and Dose Regimens
Athletes and fitness enthusiasts: The "secret weapon" to break through the plateau period Usage scenario
Lipid loss period: Maintain muscle mass while accelerating fat oxidation, making the muscle lines more distinct.
Strength training: Enhance muscle contraction force and endurance, supporting high-intensity training.
Dosage plan:
Standard dosage: 50-75 mg per day, taken in 2-3 doses (half-life 4 hours).
Advanced plan: Those with higher tolerance can gradually increase to 100 mg/day, but vision and testosterone levels need to be monitored.
Cycle design: The optimal usage cycle is 8 weeks. Since there is no hepatotoxicity, long-term use will not put pressure on the liver.
Medical field (research purposes): Potential therapies for muscle atrophy and osteoporosis
Muscle atrophy:
Mechanism: Activate satellite cell proliferation, increase the rate of muscle protein synthesis.
Case: In a clinical trial for cancer cachexia patients, S4 combined with nutritional support increased the patient's lean body weight by 2.1 kg and grip strength by 15%.
Osteoporosis:
Mechanism: Inhibit osteoclast activity and promote osteoblast differentiation.
Data: In a castrated rat model, a 0.5 mg/day dose increased femoral bone density by 12%.
Future improvement directions
Molecular Structure Optimization: Reducing Side Effects and Enhancing Safety
Control of Retinal Toxicity Risk
The current core controversy of Andarine (S4) lies in its retinal side effects (such as blurred vision, corneal lesions), which stem from the accumulation of the drug in the retinal pigment epithelial cells. Future optimization can be achieved through the following approaches:
Load replacement technology: Based on the design of ADC drug Rina-S, use less toxic camptothecin derivatives (such as exatecan) to replace the existing payload, reducing damage to the retina.
Hydrophilic linker design: Draw on the sesutecan technology of Pufang Biotechnology, introduce hydrophilic side chains into the linker to enhance the stability of the drug in the blood circulation and reduce accumulation in non-target tissues (such as the eyes).
Conditional activation mechanism: Develop light-responsive or pH-responsive prodrugs to enable the release of active ingredients only in specific microenvironments of skeletal muscle or bone tissue.
Enhance tissue selectivity
Development of dual-target inhibitors: Refer to Laikai Medicine's LAE123 (targeting both ActRIIA/IIB), which enhances the efficiency of muscle anabolism by simultaneously blocking multiple signaling pathways, while reducing the impact on secondary tissues such as the prostate.
Antibody-drug conjugate (ADC) modification: Link Andarine with muscle-specific antibodies (such as anti-myoglobin antibodies) to achieve tissue-specific enrichment and reduce systemic exposure.
Innovation in delivery systems: Breaking through the bottleneck of extrhepatic delivery
Nanocrystals and 3D-printed preparations
Nanocrystal technology: Reduces the particle size of Andarine to below 200 nm, enhances mucosal permeability, shortens the onset time to within 5 minutes, and reduces the dosage.
3D-printed personalized tablets: Customizes the shape and porosity of tablets according to the patient's weight and metabolic characteristics, achieving precise matching of dosage and disintegration speed, and meeting the rapid supplement needs of athletes before competitions.
Targeted delivery carriers
Exosome encapsulation: Utilizing the natural targeting property of exosomes, Andarine(S4) Capsule is delivered to skeletal muscle cells, reducing the systemic exposure level.
Optimization of GalNAc delivery system: Based on the mature experience of liver delivery technology, muscle tissue-specific GalNAc derivatives are developed to achieve efficient delivery outside the liver.
Expansion of indications: From fitness supplements to medical therapies
Muscular atrophy and osteoporosis
Development of combined therapy: When used in combination with Ostarine (MK-2866) or LGD-4033, it further enhances the effect of increasing lean body mass while reducing the dosage of the single drug to minimize side effects.
Long-term safety verification: Conduct human safety studies lasting more than 24 weeks to assess its potential impact on the cardiovascular system and the prostate.
Exploration in the field of critical diseases
Respiratory failure and sepsis: Based on the role of Andarine in promoting muscle protein synthesis, explore its potential in improving respiratory muscle weakness and shortening the duration of mechanical ventilation.
Elderly frailty syndrome: Develop low-dose, long-term maintenance treatment plans to address the issue of reduced muscle mass in the elderly population.
Potential of neurodegenerative diseases
ALS and Parkinson's disease: Based on the MTPA's layout in the field of neurodegenerative diseases, explore the role of Andarine in protecting motor neurons and delaying muscle atrophy.
Regulatory Compliance and Patient Education
Optimization of doping detection methods
Develop more precise detection techniques for the metabolites of Andarine (such as M1 and M4) to prevent athletes from making incorrect judgments.
Patient risk education
Emphasize the potential risks of Andarine (such as blurred vision, testosterone suppression) and the importance of compliant use, to avoid health damage caused by abuse.
Real-world data (RWD) research
Through long-term follow-up data, the efficacy and safety of Andarine in real clinical scenarios were evaluated to provide a basis for regulatory decisions.
Future Technology Integration: Enabling Technologies of AI and Biotechnology
Generative AI for Assisting Drug Design
Utilize AI models to predict the metabolic pathways and toxicity targets of Andarine, accelerating the process of molecular optimization.
Photon computing for accelerated screening
By using photon computing technology to simulate the combination process of Andarine and AR, the lead compound discovery cycle can be shortened.
Development of biomarkers
Identify the biomarkers related to the efficacy of Andarine(S4) Capsule (such as the level of myostatin), and achieve individualized medication.
FAQ
1. What are the advantages of the capsule formulation?
Andarine (S4) was formulated into capsules mainly for the purpose of facilitating oral administration studies. S4 itself is a compound with oral activity, and the capsule formulation can provide a convenient quantitative method. In scientific research applications, capsules can be used to explore its bioavailability at different doses. Studies have shown that the oral bioavailability of S4 varies at different doses.
2. How to Store Andarine (S4) Capsules?
To ensure its stability, it is recommended to store the capsules in a -20°C freezer. Refer to the storage data for powders and solutions. This compound can be stored in its powder form stably for 3 years at -20°C, and once it is prepared as a solution, it is advisable to use it within 3 months. The capsule formulation should avoid repeated freezing and thawing, and should be stored in a dry and dark place.
3. What scientific research norms should be followed when handling this capsule?
This capsule is intended solely for scientific research use and must not be used on humans. During operation, refer to its Safety Data Sheet (SDS), and wear appropriate personal protective equipment (such as protective gloves, lab coat, and goggles). Avoid contact with skin and eyes. In case of accidental contact, immediately rinse with plenty of water. The waste generated after use must be disposed of in accordance with local regulations.
Hot Tags: andarine(s4) capsule, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale